ClinicalTrials.gg
Active, not recruitingNCT07148557Updated Feb 17, 2026

A Study of Single Dose of LP-003 in Adolescent Subjects

A Phase 1/2 interventional study of LP-003 Dose 1 (Single) and LP-003 Dose 2 (Single) in Allergic Diseases, sponsored by Longbio Pharma. Active, not recruiting at 1 site in China. Open to participants aged 12 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-17.

Sponsored by Longbio Pharma · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by May 2026, 5 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
6
Allocation
Non-randomized
Ages
12 Years to 18 Years
Sex
All
01

Study summary

This is a single-center, open-label, phase Ib clinical study to evaluate the safety, pharmacokinetics and pharmacodynamic characteristics of LP-003 injection in adolescent subjects aged 12-18 years.

02

Conditions studied

  • Allergic Diseases
03

In context

Lead sponsor

Longbio Pharma is the lead sponsor of 13 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adolescent subjects aged ≥12 years and \<18 years, male or female.
  • History of allergic diseases (self-reported is acceptable), including, but not limited to, food allergies, allergic rhinitis, allergic asthma, urticaria, and atopic dermatitis.
  • Agreement to use effective during the study and for 6 months after the end of the study.
  • Subject and parent or legal guardian able to understand and voluntarily sign the form, and comply with study visits and related procedures.

Exclusion criteria

Exclusion Criteria:

  • Allergic to LP-003 or its .
  • Any serious or uncontrolled chronic disease (e.g., severe arrhythmia, ischemic heart disease, Class III/IV heart failure, severe pulmonary disease, inadequately controlled asthma, hypertension, diabetes, hypo- or hyperthyroidism) that may affect subject safety as determined by the Investigator.
  • History of severe allergic reactions.
  • Abnormal venous access, venipuncture or subcutaneous injection intolerance, history of needle or blood phobia.
  • Estimated (eGFR) \<30 mL/min/1.73m² at screening.
  • or AST > and considered by the Investigator.
  • Any other abnormal screening test result that, in the Investigator's opinion, could affect subject safety or study assessments.
  • Systemic therapy (intravenous, intramuscular, or oral) within 4 weeks prior to study drug administration.
  • Use of medications known to interact with epinephrine (e.g., β-blockers, ACE inhibitors, tricyclic antidepressants) within 4 weeks prior to administration.
  • Use of biologic products (e.g., omalizumab) within 6 months prior to administration.
  • Receipt vaccines within 14 days before administration or planning vaccination during the study.
  • Participation in other clinical trials within 3 months prior to screening or within 5 half-lives of product discontinuation (whichever is longer).
  • Any other conditions that the Investigator considers subjects unsuitable for participation in the study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Cohort 1: LP-003 Dose 1 (Single)

    Biological: LP-003 Dose 1 (Single)

  • Experimental
    Cohort 2 : LP-003 Dose 2 (Single)

    Biological: LP-003 Dose 2 (Single)

Interventions

06

What researchers measure

Primary outcomes

  1. Adverse Events (AE)

    Number of subjects with treatment-related Treatment Emergent Adverse Events (TEAEs).

    Time frame: Observation for 196 days after administration

Secondary outcomes

  1. Time to peak concentration (Tmax) of LP-003

    The time when the blood drug concentration reaches its peak after a single dose of medication.

    Time frame: Observation for 196 days after administration

  2. Maximum concentration (Cmax) of LP-003

    The maximum concentration of LP-003 in the bloodstream after administration.

    Time frame: Observation for 196 days after administration

  3. Elimination half-life (t1/2) of LP-003

    The time required for the concentration of LP-003 in the bloodstream to decrease by half.

    Time frame: Observation for 196 days after administration

  4. Area under the concentration-time curve (AUC0-t) of LP-003

    The area under the concentration-time curve (AUC) from time zero to the last chosen time point represents the integral of the drug concentration in the bloodstream over the specified duration.

    Time frame: Observation for 196 days after administration

  5. Apparent clearance rate (CL/F) of LP-003

    The ratio of drug clearance to drug concentration, represents the apparent clearance of a drug after administration, adjusted for bioavailability.

    Time frame: Observation for 196 days after administration

  6. Assessment of total immunoglobulin E (IgE)

    The changes in serum total IgE levels compared to baseline at different assessment time points.

    Time frame: Observation for 196 days after administration

  7. Assessment of free immunoglobulin E (IgE)

    The changes in serum free IgE levels compared to baseline at different assessment time points.

    Time frame: Observation for 196 days after administration

  8. Assessment of immunogenicity

    The proportion of anti drug antibody (ADA) positive subjects at different detection time points.

    Time frame: Observation for 196 days after administration

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2025 (actual). Primary completion is estimated for May 2026, 7 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2025
First posted
Aug 29, 2025
StartActual
Oct 1, 2025
Primary completionEst.
May 31, 2026
CompletionEst.
Sep 30, 2026
Last update
Feb 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07148557
Lead sponsor
Longbio Pharma
Responsible party
Sponsor
First posted
Aug 29, 2025
Start date
Oct 1, 2025
Primary completion
May 31, 2026 (estimated)
Completion
Sep 30, 2026 (estimated)
Last update
Feb 17, 2026

Study contacts

Huan Zhou
principal investigator · The First Affiliated Hospital of Anhui Medical University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: LP-003

Start the discussion